Navigation Links
Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis
Date:1/11/2010

be possibly or probably related to IR Cysteamine.
  • The proprietary, final formulation of DR Cysteamine confirmed earlier clinical trials conducted by Dr. Dohil using an enteric-coated prototype formulation of cysteamine bitartrate, which was funded by the Cystinosis Research Foundation ("CRF").
  • During the first quarter of 2010, Raptor plans to meet with the Food and Drug Administration ("FDA") and European Medicines Agency ("EMEA") to discuss plans for a repeat-dose, pivotal, Phase 3 clinical trial in cystinosis patients. Upon receiving FDA and EMEA agreements on protocol, Raptor intends to initiate its Phase 3 clinical trial at multiple sites in the US and Europe.

    Cystinosis is an inborn metabolic error characterized by the abnormal transport of cystine, an amino acid, out of the lysosomes. Failure to treat cystinosis can cause serious health consequences, including renal failure and resultant kidney transplant, growth failure, rickets, photophobia and blindness. Symptom onset typically occurs within the first year of life, when cystine crystals accumulate in various tissues and organs, including the kidneys, brain, liver, thyroid, pancreas, muscles and eyes.

    About Raptor Pharmaceutical Corp.

    Raptor Pharmaceutical Corp. (Nasdaq: RPTP) ("Raptor") is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it can have the greatest potential impact. Raptor curr
    '/>"/>

    SOURCE Raptor Pharmaceutical Corp.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Raptor Pharmaceuticals Provides Update of Product Programs
    2. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
    3. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
    4. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
    5. Raptor Pharmaceuticals Provides Update on Targeting Platforms
    6. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
    7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
    8. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
    9. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
    10. Raptor Pharmaceuticals Receives Notices of Allowance for Two NeuroTrans(TM) Patent Applications
    11. Raptor Pharmaceuticals Corp. and TorreyPines Complete Merger
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... 23, 2014 Tianyin Pharmaceutical Co., Inc. ... in patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), ... announced that the Company achieved the Public Notice ... (GMP) certificate of TPI,s Qionglai Facility (QLF) from ... public notice period is a significant procedure of ...
    (Date:12/22/2014)... 2014 NxStage Medical, Inc. (NASDAQ: ... products, announced today that the U.S. Food and ... to perform hemodialysis overnight while the patient is ... NxStage,s® System One is the first and only ... indication. Home nocturnal hemodialysis is ...
    (Date:12/22/2014)... a privately-held medical products and technologies company, today announced ... Officer of the company, effective December 22, 2014. ... Board of Directors of ConvaTec thanks Mr. Berger for ... years," said Magnus Lundberg , the Chairman of ... company is well positioned for the future."  The company ...
    Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
    ... , RIDGEFIELD, Conn., Aug. 25 ... Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran)(1) study will be ... Barcelona on Sunday, Aug. 30. The primary objective of ... investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current ...
    ... NINOVE, Belgium, August 25 20% of parents ... food) of their baby,and the accompanying discomfort (crying). Reputed ... Medical Journal" group recently,published the results of the clinical ... the Children,s gastroenterology department of the Brussels,University Hospital. , ...
    Cached Medicine Technology:Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 2Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 3Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 4Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 5Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 6Data From Largest Stroke Prevention Trial in Atrial Fibrillation To Premiere at European Society of Cardiology Congress 7Medical World Recognises New Therapy for Reflux Babies 2
    (Date:12/26/2014)... Los Angeles, CA (PRWEB) December 26, 2014 ... buyer power score of 3.1 out of 5. This ... from a low level of product specialization, low switching ... buyer power is reduced by the low availability of ... in the world price of steel and aluminum, key ...
    (Date:12/26/2014)... December 26, 2014 The Biofeedback Federation ... March 24-28, 2015 in Rome, Italy and is hosted ... workshops on a wide variety of topics ... as peak performance training in athletes. The scientific program ... world. , Biofeedback monitoring allows clients to see what ...
    (Date:12/26/2014)... 26, 2014 “Many people become overwhelmed ... injury claim issues and phone calls with insurance companies,” ... article featuring their free eBook on pedestrian and ... on pedestrian and bicycle auto accident claims assures the ... capable of professionally handling their case while they focus ...
    (Date:12/26/2014)... 2014 Pentec Health, Inc. number fourteen ... of Pennsylvania for 2014. The awards program, created in ... its kind in the country. The program is a ... of Community and Economic Development, the Pennsylvania State Council ... Central Penn Business Journal. , Charlie Wilson, ...
    (Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
    Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3
    ... and experiences early in life lead to serious acts ... found that the answer may lie in a cascading ... and new experiences that lead to yet other experiences ... found that children who had social and academic problems ...
    ... G.,Carlson, Chairman and CEO of AMERIGROUP Corporation (NYSE: AGP ... was,released November 12 by the March of Dimes:, "Every ... up in good,health. But as the March of Dimes makes ... not the case today. Studies show that babies,born prematurely often ...
    ... St. Jude while shopping this holiday ... season, ... today that it is partnering with St. Jude,during the 2008 holiday shopping season ... of participation in the,Thanks and Giving campaign, RadioShack is asking customers to "Give ...
    ... A new Web site designed to emphasize smoking prevention ... at Dartmouth (CHaD) and Dartmouth Medical School (DMS). The ... pediatrician Henry Bernstein to help prevent smoking in young ... through an unrestricted educational grant, the siteNo Smoking Room.Org ...
    ... Inc. (NYSE:,NTY) (http://www.NBTY.com ), a leading global manufacturer ... its Founder,and a member of its Board of Directors, ... portion of his NBTY stock over time, as part ... The stock,trading plan was adopted in accordance with Rule ...
    ... Amylin,Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be presenting ... on Wednesday, November,19, 2008 at 8:30 a.m. ET. Daniel ... will be providing a corporate overview., The live ... be made,available following the event. The Web cast and ...
    Cached Medicine News:Health News:Cascading effect of even minor early problems may explain serious teen violence 2Health News:AMERIGROUP Chairman and CEO Urges Action to Improve Nation's 'Premature Birth Report Card' 2Health News:RadioShack Partners With St. Jude Children's Research Hospital(R) on the 5th Anniversary of the Thanks and Giving(R) Campaign 2Health News:RadioShack Partners With St. Jude Children's Research Hospital(R) on the 5th Anniversary of the Thanks and Giving(R) Campaign 3Health News:Innovative new Web site empowers young girls to live smoke-free 2Health News:NBTY Founder Adopts Rule 10b5-1 Trading Plan 2
    For the quantitative determination of Alkaline Phosphatase in serum. Linearity: 800 IU/L at 37C. P-nitrophenyl phosphate substrate....
    Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: male: 3.5 - 7.0 mg/dL and female: 2.5 - 6.0 mg/dL. Available with calibrator and number of test 500....
    For the quantitative determination of uric acid in serum....
    ... automated, random access immunoassay ... assays available worldwide. thyroid, ... therapeutic drug, serology, anemia ... be performed on a ...
    Medicine Products: